.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX74_Belzutifan.Belzutifan .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX74_Belzutifan.Belzutifan| name: | Belzutifan |
| ATC code: | L01XX74 | route: | oral |
| n-compartments | 1 |
Belzutifan is an oral small molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α). It is approved for the treatment of von Hippel-Lindau (VHL) disease-associated renal cell carcinoma, central nervous system hemangioblastomas, and pancreatic neuroendocrine tumors that do not require immediate surgery. The drug is currently approved and in clinical use.
Pharmacokinetic parameters reported in adult patients with cancer receiving oral belzutifan 120 mg once daily.
Marathe, DD, et al., & Jain, L (2023). Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling. CPT: pharmacometrics & systems pharmacology 12(10) 1499–1510. DOI:10.1002/psp4.13028 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37596839
Marathe, DD, et al., & Jain, L (2024). Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling. Journal of clinical pharmacology 64(10) 1246–1258. DOI:10.1002/jcph.2459 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38752556